Article info
PDFMiscellanea
Journal club
Gefitinib as first-line treatment in advanced NSCLC with mutated EGFR
- Correspondence to Salma Naheed, Royal London Hospital, Whitechapel Road, Whitechapel, London, E1 8PR, UK; salma.naheed{at}gmail.com
Citation
Gefitinib as first-line treatment in advanced NSCLC with mutated EGFR
Publication history
- First published October 22, 2010.
Online issue publication
September 01, 2022
Article Versions
- Previous version (29 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.